In vitro activities of antifungal agents alone and in combination against fluconazole-susceptible and -resistant strains of Candida dubliniensis

Brazilian Journal of Infectious Diseases

Volumn 16, Issue 1, 2012, Pages 78-81

  Scheid, Liliane Alves ^a   Nunes Mario, Débora Alves ^a   Kubiça, Thaís Felli ^a   Santurio, Janio Morais ^a   Alves, Sydney Hartz ^a  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

Author keywords

Antifungal agents; Candida; Drug resistance, fungal; Fluconazole

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; RAVUCONAZOLE; TERBINAFINE; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BROTH DILUTION; CANDIDA DUBLINIENSIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CROSS RESISTANCE; DRUG ANTAGONISM; DRUG POTENTIATION; FRACTIONAL INHIBITORY CONCENTRATION; FUNGAL STRAIN; FUNGUS ISOLATION; IN VITRO STUDY; INCUBATION TIME; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STRAIN DIFFERENCE;

ANTIFUNGAL AGENTS; CANDIDA; DRUG RESISTANCE, FUNGAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FLUCONAZOLE; MICROBIAL SENSITIVITY TESTS;

EID: 84856565355     PISSN: 14138670     EISSN: 16784391     Source Type: Journal    
DOI: 10.1016/S1413-8670(12)70279-9     Document Type: Article

References (16)

1. Johnson M.D., MacDougall C., Ostrosky-Zeichner L., et al. Combination antifungal therapy. Antimicrob Agents Chemother 2004, 48:693-715.
2. Vazquez J.A. Combination antifungal therapy against Candida species: the new frontier - are we there yet?. Med Mycol 2003, 41:355-368.
3. Tariq V.N., Scott E.M., McCain N.E. Use of decimal assay for additivity to demonstrate synergy in pair combinations of econazole, nikkomycin Z, and ibuprofen against Candida albicans in vitro. Antimicrob Agents Chemother 1995, 39:2615-2619.
4. Barchiesi F., Di Francesco L.F., Compagnucci P., et al. In vitro interaction of terbinafine with amphotericin B, fluconazole and itraconazole against clinical isolates of Candida albicans. J Antimicrob Chemother 1998, 41:59-65.
5. Cantón E., Pemán J., Gobernado M., et al. Synergistic activities of fluconazole and voriconazole with terbinafine against four Candida species determined by checkerboard, time-kill, and Etest methods. Antimicrob Agents Chemother 2005, 49:1593-1596.
6. Weig M., Müller F.C. Synergism of voriconazole and terbinafine against Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob Agents Chemother 2001, 45:966-968.
7. Sullivan D.J., Westerneng T.J., Haynes K.A., et al. Candida dubliniensis sp. nov.: phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals. Microbiology 1995, 141:1507-1521.
8. Moran G.P., Sullivan D.J., Henman M.C., et al. Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV infected subjects and generation of stable fluconazole-resistant derivatives in vitro. Antimicrob Agents Chemother 1997, 41:617-623.
9. Fekete-Forgács K., Gyürc L., Lcnkcy B. Changes of virulence factors accompanying the phenomenon of induced fluconazole resistance in Candida albicans. Mycoses 1999, 43:273-279.
10. Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing yeasts 3rd ed. Approved standard M27-A3. Clinical Laboratory and Standards Institute 2008. Wayne, PA.
11. Martinez M., Lopez-Ribot J.L., Kirkpatrick W.R., et al. Replacement of Candida albicans with C. dubliniensis in human immunodeficiency virus-infected patients with oropharyngeal candidiasis treated with fluconazole. J Clin Microbiol 2002, 40:3135-3139.
12. Kirkpatrick W.R.S., Revankar S.G., McAtee R.K., et al. Detection of Candida dubliniensis in oropharyngeal samples from human immunodeficiency virus-infected patients in North America by primary CHROMagar Candida screening and susceptibility testing of isolates. J Clin Microbiol 1998, 36:3007-3012.
13. Ghannoum M.A., Elewski B. Successful treatment of fluconazole-resistant oropharyngeal candidiasis by a combination of fluconazole and terbinafine. Clin Diagn Lab Immunol 1999, 6:921-923.
14. Gil-Lamaignere C., Müller F.M.C. Differential effects of the combination of caspofungin and terbinafine against Candida albicans, Candida dubliniensis and Candida kefyr. Int J Antimicrob Agents 2004, 23:520-523.
15. Perea S., Gonzalez G., Fothergill A.W., et al. In vitro activities of terbinafine in combination with fluconazole, itraconazole, voriconazole and posaconazole against clinical isolates of Candida glabrata with decreased susceptibility to azoles. J Clin Microbiol 2002, 40:1831-1833.
16. Martin E., Maier F., Bhakdi S. Antagonistic effects of fluconazole and 5-fluorocytosine on candidacidal action of amphotericin B in human serum. Antimicrob Agents Chemother 1994, 38:1331-1338.